Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2020

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2020


Latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2020, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 13, 30, 26, 6, 125, 44 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 36 and 13 molecules, respectively.

Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Introduction
Amyotrophic Lateral Sclerosis - Overview
Amyotrophic Lateral Sclerosis - Therapeutics Development
Amyotrophic Lateral Sclerosis - Therapeutics Assessment
Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development
Amyotrophic Lateral Sclerosis - Drug Profiles
Amyotrophic Lateral Sclerosis - Dormant Projects
Amyotrophic Lateral Sclerosis - Discontinued Products
Amyotrophic Lateral Sclerosis - Product Development Milestones
Appendix

List Of Tables

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by 1st Bio Therapeutics Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by AB Science SA, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Above and Beyond Concierge Therapeutics LLC, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by AC Immune SA, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Aclipse One Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Aclipse Therapeutics LLC, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by AcuraStem Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Adare Pharma Solutions, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Affichem SA, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by AgoneX Biopharmaceuticals Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by AI Therapeutics Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by AL-S Pharma AG, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by AlphaCognition Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Alsonex Pty Ltd, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Amicogen Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Amylyx Pharmaceutical Corp, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Anavex Life Sciences Corp, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Anima Biotech Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Ankar Pharma SL, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Annexon Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Apellis Pharmaceuticals Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Apic Bio Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Apogenix AG, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Applied Genetic Technologies Corp, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Aquilus Pharmaceuticals Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Relmada Therapeutics Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by reMYND NV, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by ReoStem LLC, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Retrotope Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Revalesio Corp, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Samus Therapeutics Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Sangamo Therapeutics Inc, H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Seelos Therapeutics, Inc., H2 2020
Amyotrophic Lateral Sclerosis - Pipeline by Seneca Biopharma Inc, H2 2020
Amyotrophic Lateral Sclerosis - Dormant Projects, H2 2020
Amyotrophic Lateral Sclerosis - Discontinued Products, H2 2020

List Of Figures

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

Fill The Form For Sample Request

There is no Reviews available